Home False myths and legends in laboratory diagnostics
Article
Licensed
Unlicensed Requires Authentication

False myths and legends in laboratory diagnostics

  • Giuseppe Lippi EMAIL logo and Mario Plebani
Published/Copyright: March 23, 2013
Become an author with De Gruyter Brill
Submit Manuscript Author Information
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 51 Issue 11

Abstract

Remarkable advances in understanding human biology in health and disease, propelled by technological innovations, have contributed to an increase in the number and quality of diagnostic tests. This evolving scenario has been accompanied by the proliferation of false myths and legends in laboratory diagnostics, consuming valuable human and economic resources and jeopardizing the clinical reasoning. The aim of this article is to provide a synthetic overview about some paradigmatic examples of false beliefs in laboratory diagnostics involving activated partial thromboplastin time (APTT), cardiospecific troponins, ischemia modified albumin (IMA), D-dimer, prostate specific antigen (PSA), dibucaine number, Bence Jones protein (BJP), lipoprotein(a), neutrophil gelatinase-associated lipocalin (NGAL), potassium and reference ranges. Although the suggestive cases described in this article are not intended to be comprehensive, we hope that their description may help remove some mysticisms in laboratory diagnostics.

Keywords: diagnostics; laboratory medicine; legends; myths; test
Corresponding author: Prof. Giuseppe Lippi, Laboratory of Clinical Chemistry and Hematology, Academic Hospital of Parma, Via Gramsci, 14, 43126 Parma, Italy, Phone: +39 0521 703050, Fax: +39 0521 703791, E-mail: ,

References

1. Plebani M. Lessons from controversy: biomarkers evaluation. Clin Chem Lab Med 2013;51:247–8.10.1515/cclm-2013-0012Search in Google Scholar PubMed

2. Lippi G, Favaloro EJ, Franchini M. Laboratory diagnostics and therapy in thrombosis and hemostasis: from bedside to bench to bedside. Semin Thromb Hemost 2009;35:3–8.10.1055/s-0029-1214143Search in Google Scholar PubMed

3. Lippi G, Favaloro EJ. Laboratory hemostasis: milestones in clinical chemistry and laboratory medicine. Clin Chem Lab Med 2013;51:91–7.10.1515/cclm-2012-0387Search in Google Scholar PubMed

4. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 2010;21:459–63.10.1097/MBC.0b013e328338dbe8Search in Google Scholar

5. Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008;34:604–11.10.1055/s-0028-1104539Search in Google Scholar PubMed

6. Adcock Funk DM, Lippi G, Favaloro EJ. Quality standards for sample processing, transportation, and storage in hemostasis testing. Semin Thromb Hemost 2012;38:576–85.10.1055/s-0032-1319768Search in Google Scholar PubMed

7. Lippi G, Salvagno GL, Montagnana M, Lima-Oliveira G, Guidi GC, Favaloro EJ. Quality standards for sample collection in coagulation testing. Semin Thromb Hemost 2012;38:565–75.10.1055/s-0032-1315961Search in Google Scholar PubMed

8. Lippi G, Franchini M, Poli G, Salvagno GL, Montagnana M, Guidi GC. Is the activated partial thromboplastin time suitable to screen for von Willebrand factor deficiencies? Blood Coagul Fibrinolysis 2007;18:361–4.10.1097/MBC.0b013e32810fd872Search in Google Scholar PubMed

9. Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med 2007;45:2–12.10.1515/CCLM.2007.006Search in Google Scholar PubMed

10. Lippi G, Franchini M, Brazzarola P, Manzato F. Preoperative screening: the rationale of measuring APTT in risk assessment. Haematologica 2001;86:328.Search in Google Scholar

11. Renné T, Schmaier AH, Nickel KF, Blombäck M, Maas C. In vivo roles of factor XII. Blood 2012;120:4296–303.10.1182/blood-2012-07-292094Search in Google Scholar PubMed PubMed Central

12. Cei M, Mumoli N, Giuntoli S, Marino O, Pasquinelli P, Taddei P, et al. Concomitant ST-elevation myocardial infarction and deep vein thrombosis in a patient with severe factor XII deficiency: case report and review of the literature. Q J Med 2011;104:1083–6.10.1093/qjmed/hcq221Search in Google Scholar PubMed

13. Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012;38:375–84.10.1055/s-0032-1311991Search in Google Scholar PubMed

14. Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts? Semin Thromb Hemost 2012;38:322–7.10.1055/s-0032-1304719Search in Google Scholar PubMed

15. Lippi G, Favaloro EJ, Franchini M. Paradoxical thrombosis part 1: factor replacement therapy, inherited clotting factor deficiencies and prolonged APTT. J Thromb Thrombolysis 2012;34:360–6.10.1007/s11239-012-0753-3Search in Google Scholar PubMed

16. Lippi G. Biomarkers of myocardial ischemia in the emergency room: cardiospecific troponin and beyond. Eur J Intern Med 2013;24:97–9.10.1016/j.ejim.2012.10.012Search in Google Scholar PubMed

17. Lippi G, Franchini M, Cervellin G. Diagnosis and management of ischemic heart disease. Semin Thromb Hemost 2013;39:202–13.10.1055/s-0032-1333543Search in Google Scholar PubMed

18. Cardinaels EP, Mingels AM, Jacobs LH, Meex SJ, Bekers O, van Dieijen-Visser MP. A comprehensive review of upper reference limits reported for (high-)sensitivity cardiac troponin assays: the challenges that lie ahead. Clin Chem Lab Med 2012;50:791–806.10.1515/cclm-2011-0895Search in Google Scholar PubMed

19. Dimeski G, Jones B, Brown N. Carryover can be a cause of false-positive results with the Beckman AccuTnI assay. Clin Chem Lab Med 2012;50:1135–6.10.1515/cclm-2011-8838Search in Google Scholar PubMed

20. Lippi G, Cervellin G. Degradation of troponin I in serum or plasma: mechanisms, and analytical and clinical implications. Semin Thromb Hemost 2012;38:222–9.10.1055/s-0032-1301419Search in Google Scholar PubMed

21. Lippi G, Avanzini P, Dipalo M, Aloe R, Cervellin G. Influence of hemolysis on troponin testing: studies on Beckman Coulter UniCel Dxl 800 Accu-TnI and overview of the literature. Clin Chem Lab Med 2011;49:2097–100.10.1515/CCLM.2011.703Search in Google Scholar PubMed

22. Dimeski G. Evidence on the cause of false positive troponin I results with the Beckman AccuTnI method. Clin Chem Lab Med 2011;49:1079–80.10.1515/CCLM.2011.163Search in Google Scholar PubMed

23. Michielsen EC, Bisschops PG, Janssen MJ. False positive troponin result caused by a true macrotroponin. Clin Chem Lab Med 2011;49:923–5.10.1515/CCLM.2011.147Search in Google Scholar PubMed

24. Lackner KJ. Laboratory diagnostics of myocardial infarction – troponins and beyond. Clin Chem Lab Med 2013;51:83–9.10.1515/cclm-2012-0572Search in Google Scholar PubMed

25. Lippi G, Cervellin G. Identification of troponin determinants for improving its diagnostic performance in the emergency department. J Emerg Med 2012;43:e487–8.10.1016/j.jemermed.2012.05.016Search in Google Scholar PubMed

26. Lippi G, Margapoti R, Aloe R, Cervellin G. Highly-sensitive troponin I in patients admitted to the emergency room with acute infections. Eur J Intern Med 2013 Feb 15. doi: 10.1016/ j.ejim.2013.01.019. [Epub ahead of print].10.1016/j.ejim.2013.01.019.[Epub]Search in Google Scholar

27. Lippi G, Dipalo M, Carbucicchio A, Aloe R, Benatti M, Cervellin G. The concentration of highly-sensitive troponin I is increased in patients with brain injury after mild head trauma. Int J Cardiol 2013 Feb 7. doi:10.1016/j.ijcard.2013.01.018. [Epub ahead of print].10.1016/j.ijcard.2013.01.018.[Epub]Search in Google Scholar

28. Lippi G, Cervellin G, Banfi G, Plebani M. Cardiac troponins and physical exercise. It’s time to make a point. Biochem Med (Zagreb) 2011;21:55–62.10.11613/BM.2011.012Search in Google Scholar PubMed

29. Giannoni A, Giovannini S, Clerico A. Measurement of circulating concentrations of cardiac troponin I and T in healthy subjects: a tool for monitoring myocardial tissue renewal? Clin Chem Lab Med 2009;47:1167–77.10.1515/CCLM.2009.320Search in Google Scholar PubMed

30. Lippi G, Franchini M, Targher G. Arterial thrombus formation in cardiovascular disease. Nat Rev Cardiol 2011;8:502–12.10.1038/nrcardio.2011.91Search in Google Scholar PubMed

31. Lippi G, Montagnana M, Guidi GC. Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol 2006;108:410–1.10.1016/j.ijcard.2005.03.040Search in Google Scholar PubMed

32. Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes – review and clinical implications. Clin Chem Lab Med 2011;49:177–84.10.1515/CCLM.2011.037Search in Google Scholar PubMed

33. Lippi G, Montagnana M. Ischemia-modified albumin in ischemic disorders. Ann Thorac Cardiovasc Surg 2009;15:137.Search in Google Scholar

34. Aslanand D, Apple FS. Ischemia modified albumin measured by the albumin cobalt binding test: a clinical and analytical review. Lab Medicine 2004;35:44–7.10.1309/XXYETJN8YM9HBD9CSearch in Google Scholar

35. Lin S, Yokoyama H, Rac VE, Brooks SC. Novel biomarkers in diagnosing cardiac ischemia in the emergency department: a systematic review. Resuscitation 2012;83:684–91.10.1016/j.resuscitation.2011.12.015Search in Google Scholar PubMed

36. Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia-modified albumin in routine clinical practice. Biomarkers 2010;15:655–62.10.3109/1354750X.2010.513449Search in Google Scholar PubMed

37. Hakligör A, Kösem A, Seneş M, Yücel D. Effect of albumin concentration and serum matrix on ischemia-modified albumin. Clin Biochem 2010;43:345–8.10.1016/j.clinbiochem.2009.09.006Search in Google Scholar PubMed

38. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischemia-modified albumin testing: adjustment for serum albumin. Clin Chem Lab Med 2007;45:261–2.10.1515/CCLM.2007.039Search in Google Scholar PubMed

39. Hausen BS, Signor C, Kober H, Tatsch E, Pereira RS, Duarte T, et al. Effect of temperature on albumin cobalt binding and its influence on ischemia-modified albumin levels in patients with suspected acute coronary syndrome. Clin Lab 2012;58:169–72.Search in Google Scholar

40. Lippi G, Cervellin G, Franchini M, Favaloro EJ. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. J Thromb Thrombolysis 2010;30: 459–71.10.1007/s11239-010-0460-xSearch in Google Scholar PubMed

41. Lippi G, Mengoni A, Manzato F. Plasma D-dimer in the diagnosis of deep vein thrombosis. J Am Med Assoc 1998;280:1828–9.10.1001/jama.280.21.1828-bSearch in Google Scholar PubMed

42. Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, Doctor! My D-dimer is raised. Ann Med 2008;40:594–605.10.1080/07853890802161015Search in Google Scholar PubMed

43. Lippi G, Favaloro EJ. D-dimer measurement and laboratory feedback. J Emerg Med 2009;37:82–3.10.1016/j.jemermed.2008.07.033Search in Google Scholar PubMed

44. Montagnana M, Cervellin G, Franchini M, Lippi G. Pathophysiology, clinics and diagnostics of non-thrombotic pulmonary embolism. J Thromb Thrombolysis 2011;31:436–44.10.1007/s11239-010-0519-8Search in Google Scholar

45. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10–29.10.3322/caac.20138Search in Google Scholar

46. Brooks DD, Wolf A, Smith RA, Dash C, Guessous I. Prostate cancer screening 2010: updated recommendations from the American Cancer Society. J Natl Med Assoc 2010;102:423–9.10.1016/S0027-9684(15)30578-2Search in Google Scholar

47. Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762–71.10.7326/0003-4819-155-11-201112060-00375Search in Google Scholar PubMed

48. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al; European Association of Urology. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61–7110.1016/j.eururo.2010.10.039Search in Google Scholar PubMed

49. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2013;189(1 Suppl):S2–11.10.1016/j.juro.2012.11.014Search in Google Scholar PubMed

50. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al; Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.10.1056/NEJMoa1113162Search in Google Scholar PubMed PubMed Central

51. Heijnsdijk EA, Wever EM, Auvinen A, Hugosson J, Ciatto S, Nelen V, et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012;367:595–605.10.1056/NEJMoa1201637Search in Google Scholar PubMed PubMed Central

52. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al; ERSPC Investigators. Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 2012;366:981–90.10.1056/NEJMoa1113135Search in Google Scholar PubMed PubMed Central

53. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schröder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003;95:868–78.10.1093/jnci/95.12.868Search in Google Scholar PubMed

54. Filella X, Giménez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med 2013;51:729–39.10.1515/cclm-2012-0410Search in Google Scholar PubMed

55. Lippi G, Aloe R, Mattiuzzi C. Prostate-Specific Antigen (PSA) Isoform p2PSA in prostate cancer screening: systematic review of current evidence and further perspectives. Riv Ital Med Lab 2012;8:231–8.10.1007/s13631-012-0067-7Search in Google Scholar

56. Zambon CF, Prayer-Galetti T, Basso D, Padoan A, Rossi E, Secco S, et al. Effectiveness of the combined evaluation of KLK3 genetics and free-to-total prostate specific antigen ratio for prostate cancer diagnosis. J Urol 2012;188:1124–30.10.1016/j.juro.2012.06.030Search in Google Scholar PubMed

57. Soliday FK, Conley YP, Henker R. Pseudocholinesterase deficiency: a comprehensive review of genetic, acquired, and drug influences. AANA J 2010;78:313–20.Search in Google Scholar

58. Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase; determination of dibucaine numbers. Can J Biochem Physiol 1957;35:339–46.10.1139/o57-041Search in Google Scholar

59. Lee C, Katz RL. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux! J Crit Care 2009;24:43–9.10.1016/j.jcrc.2008.08.009Search in Google Scholar PubMed

60. Graziani M, Merlini G, Petrini C; for the IFCC Committee on Plasma Proteins and the SIBioC Study Group on Proteins Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003;41:338–46.10.1515/CCLM.2003.054Search in Google Scholar PubMed

61. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992;183:519–21.10.1148/radiology.183.2.1561361Search in Google Scholar PubMed

62. Lencioni R, Fattori R, Morana G, Stacul F. Contrast-induced nephropathy in patients undergoing computed tomography (CONNECT) – a clinical problem in daily practice? A multicenter observational study. Acta Radiol 2010;51:741–50.10.3109/02841851.2010.495350Search in Google Scholar PubMed

63. Pahade JK, LeBedis CA, Raptopoulos VD, Avigan DE, Yam CS, Kruskal JB, et al. Incidence of contrast-induced nephropathy in patients with multiple myeloma undergoing contrast-enhanced CT. AJR Am J Roentgenol 2011;196: 1094–101.10.2214/AJR.10.5152Search in Google Scholar PubMed

64. Thomsen HS; European Society of Urogenital Radiology. European Society of Urogenital Radiology guidelines on contrast media application. Curr Opin Urol 2007;17:70–6.10.1097/MOU.0b013e328011c96fSearch in Google Scholar PubMed

65. Lippi G, Guidi G. Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003;40:1–42.10.1080/713609328Search in Google Scholar PubMed

66. Lippi G, Franchini M, Targher G. Screening and therapeutic management of lipoprotein(a) excess: review of the epidemiological evidence, guidelines and recommendations. Clin Chim Acta 2011;412:797–801.10.1016/j.cca.2011.01.018Search in Google Scholar PubMed

67. Berg K. Immunochemical studies of the Lp(a) factor. Acta Pathol Microbiol Scand 1964;62:600–12.10.1111/apm.1964.62.4.600Search in Google Scholar PubMed

68. Lippi G, Guidi G. Lipoprotein(a): from ancestral benefit to modern pathogen? Q J Med 2000;93:75–84.10.1093/qjmed/93.2.75Search in Google Scholar PubMed

69. Lippi G, Targher G, Salvagno GL, Montagnana M, Franchini M, Guidi GC. Lipoprotein(a) and ageing. Clin Lab 2010;56: 463–6.Search in Google Scholar

70. Lippi G, Franchini M, Salvagno GL, Guidi GC. Lipoprotein[a] and cancer: anti-neoplastic effect besides its cardiovascular potency. Cancer Treat Rev 2007;33:427–36.10.1016/j.ctrv.2007.02.006Search in Google Scholar PubMed

71. Lippi G, Franchini M, Guidi GC. Lipoprotein(a), athero-thrombosis and longevity. A historical paradox finally elucidated? Haematologica 2007;92:e48.10.3324/haematol.11206Search in Google Scholar PubMed

72. Lippi G, Plebani M. Neutrophil gelatinase-associated lipocalin (NGAL): the laboratory perspective. Clin Chem Lab Med 2012;50:1483–7.10.1515/cclm-2012-0344Search in Google Scholar PubMed

73. Lippi G, Aloe R, Storelli A, Cervellin G, Trenti T. Evaluation of NGAL Test™, a fully-automated neutrophil gelatinase-associated lipocalin (NGAL) immunoassay on Beckman Coulter AU 5822. Clin Chem Lab Med 2011;50:1581–4.10.1515/cclm.2011.839Search in Google Scholar

74. Cavalier E, Bekaert AC, Carlisi A, Legrand D, Krzesinski JM, Delanaye P. Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory’s point of view. Clin Chem Lab Med 2011;49:339–41.10.1515/CCLM.2011.044Search in Google Scholar PubMed

75. Cervellin G, di Somma S. Neutrophil gelatinase-associated lipocalin (NGAL): the clinician’s perspective. Clin Chem Lab Med 2012;50:1489–93.10.1515/cclm-2012-0433Search in Google Scholar PubMed

76. Clerico A, Galli C, Fortunato A, Ronco C. Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med 2012;50:1505–17.10.1515/cclm-2011-0814Search in Google Scholar PubMed

77. Makris K, Rizos D, Kafkas N, Haliassos A. Neurophil gelatinase-associated lipocalin as a new biomarker in laboratory medicine. Clin Chem Lab Med 2012;50:1519–32.10.1515/cclm-2012-0227Search in Google Scholar PubMed

78. Cruz DN, Gaiao S, Maisel A, Ronco C, Devarajan P. Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systematic review. Clin Chem Lab Med 2012;50: 1533–45.10.1515/cclm-2012-0307Search in Google Scholar PubMed PubMed Central

79. Lippi G, Cervellin G. The predictive value of plasma neutrophil gelatinase-associated lipocalin on cardiovascular death and all-cause mortality might be mediated by leukocytosis. J Am Coll Cardiol 2012;60:564.10.1016/j.jacc.2012.03.064Search in Google Scholar PubMed

80. Lippi G, Caleffi A, Pipitone S, Elia G, Ngah A, Aloe R, et al. Assessment of neutrophil gelatinase-associated lipocalin and lactate dehydrogenase in peritoneal fluids for the screening of bacterial peritonitis. Clin Chim Acta 2013;418C:59–62.10.1016/j.cca.2012.12.020Search in Google Scholar PubMed

81. Bolignano D. Serum creatinine and the search for new biomarkers of acute kidney injury (AKI): the story continues. Clin Chem Lab Med 2012;50:1495–9.10.1515/cclm-2012-0099Search in Google Scholar PubMed

82. Rastegar A. Serum potassium. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations. 3rd ed. Boston: Butterworths, 1990:chapter 195.Search in Google Scholar

83. Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol 2011;26:377–84.10.1007/s00467-010-1699-3Search in Google Scholar PubMed PubMed Central

84. Cervellin G, Comelli I, Lippi G. Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features. Clin Chem Lab Med 2010;48:749–56.10.1515/CCLM.2010.151Search in Google Scholar PubMed

85. Lippi G, Becan-McBride K, Behúlová D, Bowen RA, Church S, Delanghe J, et al. Preanalytical quality improvement: in quality we trust. Clin Chem Lab Med 2013;51:229–41.10.1515/cclm-2012-0597Search in Google Scholar PubMed

86. Lippi G, Plebani M, Di Somma S, Cervellin G. Hemolyzed specimens: a major challenge for emergency departments and clinical laboratories. Crit Rev Clin Lab Sci 2011;48:143–53.10.3109/10408363.2011.600228Search in Google Scholar PubMed

87. Stankovic AK, Smith S. Elevated serum potassium values: the role of preanalytic variables. Am J Clin Pathol 2004;121(Suppl):S105–12.10.1309/UEPQUM11WH9P8JNYSearch in Google Scholar PubMed

88. Clinical and Laboratory Standards Institute. Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline, 3rd ed. CLSI document C28-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.Search in Google Scholar

89. Plebani M, Lippi G. Reference values and the journal: why the past is now present. Clin Chem Lab Med 2012;50:761–3.10.1515/cclm-2012-0089Search in Google Scholar PubMed

90. Siest G, Henny J, Gräsbeck R, Wilding P, Petitclerc C, Queraltó JM, et al. The theory of reference values: an unfinished symphony. Clin Chem Lab Med 2013;51:47–64.10.1515/cclm-2012-0682Search in Google Scholar PubMed

91. Panteghini M, Ceriotti F. Obtaining reference intervals traceable to reference measurement systems: is it possible, who is responsible, what is the strategy? Clin Chem Lab Med 2011;50:813–7.10.1515/cclm.2011.828Search in Google Scholar PubMed

92. Ceriotti F. Common reference intervals: the IFCC position. Clin Biochem 2009;42:297.10.1016/j.clinbiochem.2008.09.017Search in Google Scholar PubMed

93. Ceriotti F. Establishing pediatric reference intervals: a challenging task. Clin Chem 2012;58:808–10.10.1373/clinchem.2012.183483Search in Google Scholar PubMed

94. Fraser CG, Lippi G, Plebani M. Reference change values may need some improvement but are invaluable tools in laboratory medicine. Clin Chem Lab Med 2012;50:963–4.10.1515/cclm.2011.826Search in Google Scholar

95. Fraser CG. Reference change values. Clin Chem Lab Med 2011;50:807–12.10.1515/cclm.2011.733Search in Google Scholar

96. Cheuvront SN, Fraser CG, Kenefick RW, Ely BR, Sawka MN. Reference change values for monitoring dehydration. Clin Chem Lab Med 2011;49:1033–7.10.1515/CCLM.2011.170Search in Google Scholar PubMed

Received: 2013-02-07
Accepted: 2013-02-26
Published Online: 2013-03-23
Published in Print: 2013-11-01

©2013 by Walter de Gruyter Berlin Boston

Articles in the same Issue

  1. Letter to the Editor
  2. Elevated level of cell-free plasma DNA is associated with advanced-stage breast cancer and metastasis
  3. Is procalcitonin a reliable marker of sepsis in critically ill septic patients undergoing continuous veno-venous hemodiafiltration with “high cut-off” membranes (HCO-CVVHDF)?
  4. Challenging our serological algorithm for celiac disease (CD) diagnosis by the ESPGHAN guidelines
  5. Preanalytical quality control in a university hospital in China
  6. Racial differences and relationships between gestational thyrotropin and free thyroxine in a multiracial Asian population
  7. Analytical performance and method comparison study of the total homocysteine immunoassay on the AIA 600II analyser
  8. Easy verification of clinical chemistry reference intervals
  9. The Elecsys® Vitamin B12 assay is not affected by anti-intrinsic factor antibodies
  10. Chemiluminescence-based cobalamin assay errors: background and perspectives
  11. Congress Abstracts
  12. Abstracts IV Italian Great Network Congress Rome, 14th–18th October 2013*)
  13. Masthead
  14. Masthead
  15. Editorial
  16. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT)
  17. From “panic” to “critical” values: which path toward harmonization?
  18. Review
  19. Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?
  20. Opinion Paper
  21. False myths and legends in laboratory diagnostics
  22. General Clinical Chemistry and Laboratory Medicine
  23. National survey on critical values notification of 599 institutions in China
  24. Influence of physical properties of cuvette surface on measurement of serum lipase
  25. Red cell indices: differentiation between β-thalassemia trait and iron deficiency anemia and application to sickle-cell disease and sickle-cell thalassemia
  26. Measurement of immature platelets with Abbott CD-Sapphire and Sysmex XE-5000 in haematology and oncology patients
  27. Performance characteristics of consensus approaches for small and minor paroxysmal nocturnal hemoglobinuria clone determination by flow cytometry
  28. Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener’s)
  29. The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies
  30. Reference Values and Biological Variations
  31. Reference interval studies: what is the maximum number of samples recommended?
  32. Short-term estimation and application of biological variation of small dense low-density lipoproteins in healthy individuals
  33. Cancer Diagnostics
  34. Diagnostic inconsistency of faecal immunochemical tests for haemoglobin in population screening of colorectal cancer
  35. Cardiovascular Diseases
  36. Comparison of the 99th percentiles of three troponin I assays in a large reference population
  37. Assessment of plasma aminothiol levels and the association with recurrent atherothrombotic events in patients hospitalized for an acute coronary syndrome: a prospective study
  38. Diabetes
  39. The relationship between estimated average glucose and fasting plasma glucose
  40. Evaluation of enzymatic BM Test HbA1c on the JCA-BM6010/C and comparison with Bio-Rad Variant II Turbo, Tosoh HLC 723 G8, and AutoLab immunoturbidimetry assay
https://doi.org/10.1515/cclm-2013-0105
Keywords for this article
diagnostics; laboratory medicine; legends; myths; test

Articles in the same Issue

  1. Letter to the Editor
  2. Elevated level of cell-free plasma DNA is associated with advanced-stage breast cancer and metastasis
  3. Is procalcitonin a reliable marker of sepsis in critically ill septic patients undergoing continuous veno-venous hemodiafiltration with “high cut-off” membranes (HCO-CVVHDF)?
  4. Challenging our serological algorithm for celiac disease (CD) diagnosis by the ESPGHAN guidelines
  5. Preanalytical quality control in a university hospital in China
  6. Racial differences and relationships between gestational thyrotropin and free thyroxine in a multiracial Asian population
  7. Analytical performance and method comparison study of the total homocysteine immunoassay on the AIA 600II analyser
  8. Easy verification of clinical chemistry reference intervals
  9. The Elecsys® Vitamin B12 assay is not affected by anti-intrinsic factor antibodies
  10. Chemiluminescence-based cobalamin assay errors: background and perspectives
  11. Congress Abstracts
  12. Abstracts IV Italian Great Network Congress Rome, 14th–18th October 2013*)
  13. Masthead
  14. Masthead
  15. Editorial
  16. Making colorectal cancer screening FITTER for purpose with quantitative faecal immunochemical tests for haemoglobin (FIT)
  17. From “panic” to “critical” values: which path toward harmonization?
  18. Review
  19. Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?
  20. Opinion Paper
  21. False myths and legends in laboratory diagnostics
  22. General Clinical Chemistry and Laboratory Medicine
  23. National survey on critical values notification of 599 institutions in China
  24. Influence of physical properties of cuvette surface on measurement of serum lipase
  25. Red cell indices: differentiation between β-thalassemia trait and iron deficiency anemia and application to sickle-cell disease and sickle-cell thalassemia
  26. Measurement of immature platelets with Abbott CD-Sapphire and Sysmex XE-5000 in haematology and oncology patients
  27. Performance characteristics of consensus approaches for small and minor paroxysmal nocturnal hemoglobinuria clone determination by flow cytometry
  28. Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener’s)
  29. The integration of the detection of systemic sclerosis-associated antibodies in a routine laboratory setting: comparison of different strategies
  30. Reference Values and Biological Variations
  31. Reference interval studies: what is the maximum number of samples recommended?
  32. Short-term estimation and application of biological variation of small dense low-density lipoproteins in healthy individuals
  33. Cancer Diagnostics
  34. Diagnostic inconsistency of faecal immunochemical tests for haemoglobin in population screening of colorectal cancer
  35. Cardiovascular Diseases
  36. Comparison of the 99th percentiles of three troponin I assays in a large reference population
  37. Assessment of plasma aminothiol levels and the association with recurrent atherothrombotic events in patients hospitalized for an acute coronary syndrome: a prospective study
  38. Diabetes
  39. The relationship between estimated average glucose and fasting plasma glucose
  40. Evaluation of enzymatic BM Test HbA1c on the JCA-BM6010/C and comparison with Bio-Rad Variant II Turbo, Tosoh HLC 723 G8, and AutoLab immunoturbidimetry assay
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 26.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2013-0105/html
Scroll to top button